EFM
DSGN icon

E Fund Management’s Design Therapeutics DSGN Stock Holding History

E Fund Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-12,523
Closed -$128K – 337
2022
Q4 		$128K Buy
+12,523
New +$170K 0.01% 319

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

E Fund Management's DSGN Position: Q1 2023 in Review

E Fund Management sold out of Design Therapeutics (DSGN) in Q1 2023, closing a stake of 12,523 shares — an estimated $128K sold.

E Fund Management first reported a position in DSGN in Q4 2022 and held it in 1 quarter. The position peaked at $128K in Q4 2022. 96 funds tracked by Wall St. Rank hold DSGN as of Q1 2023.

  • E Fund Management reported no remaining Design Therapeutics position as of Q1 2023 after selling out during the quarter.
  • E Fund Management sold 12,523 Design Therapeutics shares in Q1 2023, an estimated $128K.
  • E Fund Management first reported a position in Design Therapeutics in Q4 2022 and held it in 1 quarter.
  • E Fund Management's Design Therapeutics position peaked at $128K in Q4 2022.
  • 96 funds tracked by Wall St. Rank held Design Therapeutics as of Q1 2023.

Based on E Fund Management's 13F filing for Q1 2023, filed 11 May 2023.